By Fineline Cube 
China-based TenNor Therapeutics (Suzhou) Limited announced the submission of its listing application to the Main Board of the Hong Kong Stock Exchange on July 30, 2025. CITIC Securities and ABC International are serving as joint sponsors for the listing.
Company Overview
Founded in 2012, TenNor Therapeutics is a biotechnology company nearing commercialization. It specializes in the development of differentiated innovative drugs for bacterial infections and metabolism-related diseases. The company is equipped with a proprietary multi-target conjugated molecule technology platform and has established a robust pipeline of seven innovative assets.
Core Products
TNP-2198 (Rifabutin Nitazoxanide)
- The world’s first new molecular entity candidate for treating H. pylori infection, featuring a multi-target synergistic mechanism.
- Phase III China registration clinical trial completed; New Drug Application (NDA) expected to be submitted in China before the end of August 2025.
TNP-2092 Injection (Rifabutin Quinolone)
- A potential first-in-class triple-target antibacterial drug for implant-related bacterial infections.
TNP-2092 Oral Formulation
- Designed for the treatment of metabolism-related diseases involving the gut microbiome.
Commercialization and Clinical Success
In 2023, TenNor Therapeutics signed a commercialization agreement for TNP-2198 with Grand Life Science. According to registration clinical trial data, TNP-2198 triple therapy (RTT) demonstrated superior efficacy, safety, and compliance compared to bismuth quadruple therapy (BQT), particularly in patients with multi-drug resistance.
Financial Overview
As of March 31, 2025, TenNor Therapeutics reported cash and cash equivalents of RMB 146 million and net current liabilities of RMB 932 million. The company has completed seven rounds of financing, raising a cumulative RMB 733 million. Following its Series E round in March 2025, the company achieved a post-money valuation of RMB 2.013 billion.-Fineline Info & Tech